Huaxu Pharm

Huaxu Pharmaceutical is a clinical-stage biotechnology company based in Beijing, China, specializing in the discovery and development of innovative small molecule therapeutics. The company's primary focus is on metabolic diseases and oncology, with a leading program targeting hyperuricemia and gout. Its flagship candidate, HX001, is a potent URAT1 inhibitor designed to provide superior efficacy and safety compared to existing treatments. Huaxu leverages its internal R&D capabilities to advance a pipeline of candidates through clinical trials, aiming to address significant unmet medical needs in the global market. The company is backed by prominent venture capital firms and continues to expand its portfolio into diverse therapeutic areas.